Member Info for RevoltingPeasant

Positive piece in today's on line IC report. Even allowing for the legal decision, BTG still materially undervalued: BTG�s (BTG) varicose veins treatment Varithena has finally been assigned a permanent insurance code in the US. Doctors who implement the procedure will be entitled to up to $1,697 (�1,292) reimbursement via the government�s Medicare and Medicaid insurance programmes, meaning prescription is now expected to pick up. Varithena insurance has been the thorn in BTG�s side since 2015 when the treatment was first launched in the US. Originally, its temporary code meant doctors could only expect up to $1,129 back from the insurers, short of the $3,000 it costs for use on multiple veins. Without guaranteed reimbursement, doctors have been reluctant to prescribe Varithena and sales have fallen far short of expectations during the past two years. But even with these new codes, broker Panmure Gordon remains cautious about forecasting an uptick in sales due to competition in the market. And even chief executive Louise Makin is still reluctant to get excited, warning that the impact on physician adoption and insurer practice might not become clear before the end of 2018. Investor enthusiasm for the announcement was also dampened by news that BTG will have to take a �53.5m provision in its upcoming first-half results due to problems surrounding another product. A Delaware court has found the group guilty of breaching the terms of its distribution agreement with peer WellStat, regarding chemotherapy toxicology treatment Vistogard. WellStat claimed the UK group had failed to invest in a large enough sales force in the US. BTG has been forced to pay damages and will lose the US rights to the treatment. BTG is considering its appeal options. Considering Vistogard only contributed �3.5m of sales in the year to March 2017, this news won�t have muddied the outlook too much. However, the one-off provision is sure to impact half-year results, due on 14 November. IC View Poor publicity regarding a small number of insignificant drugs has dogged BTG�s share price for the past few years. The shares are up on solidly our recent buy tip (652p, 25 May 2017). Although some sentiment has been recovered by the promise of new Varithena codes, we think the shares� forward earnings valuation of 25 times � far below the top of its five-year valuation range � fails to account for the growth available in some of BTG�s key markets. Buy."

Price drop seems an over-reaction to me. I've taken the opportunity to top up. Hope I'm right!

Profit taking may be contributed to by item in Questor in today's Telegraph: "Update: Watkin Jones Shares in Watkin Jones, the student accommodation specialist, have risen by almost 90pc since we tipped them in January and now feels like a good time to bank a profit. This is not to say anything is going wrong � far from it. Last week�s year-end trading update read very well. Results for the year just ended are due to meet expectations, all 10 developments scheduled for delivery in the new financial year have been forward sold and five more have already been forward sold for 2019. But this good visibility means positive surprises are unlikely, at least in the near term, and the stock�s stunning run means it is no longer as cheap as it was. A forward price to earnings ratio of nearly 16 for fiscal 2018 represents a big premium to the mainstream builders, while the shares yield less, at 3pc, than building peers and the index. This is a well-run company that is doing everything right but banking a substantial profit seems like a prudent plan given the valuation. Questor says: take profits" Having seen the price double since I bought in, I have sold half and so now have a free carry for the balance. Saves chewing fingernails down to the quick!

Looks like the print copy of IC had an effect today. Nice to see a 6% rise. Onwards and upwards to the interims (I hope).

Hooray! For the first time since I bought just over 2 years ago, I'm in profit (just). What shall I spend my �25 on?

Bango is a "tip of the week" in tomorrow's IC. Previously tipped by Simon Thompson, this new article is by another reporter. Should help the SP.

Positive item in today's IC on line: Shares in Watkin Jones (WJG) moved up 3 per cent after the student accommodation developer delivered an upbeat trading update for the year to September 2017. All the group�s 10 student schemes have been completed on time, totalling 3,314 beds, while the 10 schemes for the year to September 2018 covering 3,415 beds have already been forward sold. In addition, nearly three-quarters of all schemes for the following year have also been forward sold. Looking further ahead, there are eight secured development sites for 2,959 beds targeted for delivery from 2019 to 2021. There has also been solid progress by Watkin Jones in developing its presence in the build-to-rent sector. Three development sites have been secured, and the company is in negotiations on several other opportunities, from which it is hoping to develop around 1,500 units between 2018 and 2022 subject to securing planning consent. As well as building forward-funded schemes, Watkin Jones also operates a student accommodation management service, whereby universities pay them to manage the student blocks after completion. Trading under the names of Fresh Student Living and Five Nine Living, it now manages 16,082 student beds across 53 schemes under management, up from 12,337 a year earlier. IC View Watkin Jones has a solid pipeline offering considerable earnings visibility. What�s more, this is a very capital-light business model that minimises risk and makes it easier to scale up its operations. There is also fast-growing institutional interest in the build-to-rent sector. At 235p, the shares are up from our buy tip (195.25p, 29 June 2017), and we�re sticking with that. Buy.

Recommended by Simon Thompson in IC on line this lunchtime. He references an earlier article which has a price target of 60p. Says buy in anticipation of interims on 17 November

Today's rise to a 52 week high at 23p may be due in part to a reiteration of his buy recommendation by Simon Thompson in the IC on line today. He has shifted his target price from 24p to 30 - 33p.

Just back from a few days away and looking at Friday's closing trades. Has anyone else noticed 7.6million shares traded on Wednesday but not reported until after Friday's close? Possibly buys as price was 18 - 19p on Wednesday. Someone was keen.

Anyone any idea what's going on? 52 week high of 137p in June and fairly steady after that until about 3 weeks ago. Now drifting down almost daily - down about 20%, despite positive trading update in July, acquisition in September and good half year results also in September. This is getting depressing!

Volume now 3 times daily average and bid/ask 19.25/20p

Another un-named government contract. At least this time its European! This share is long overdue for a re-rating.

Simon Thompson in Investors Chronicle on line has this as a hold after today's RNS. The fall is overdone in his view. Also, I note that the share buybacks seem to have started again today, presumably taking advantage of the fall. 120,000 bought back today. There is plenty of cash on the balance sheet to fund this. Should help to keep a floor under the SP. I'm holding.

Simon Thompson reviews Bango's results in his on line column today. The company has reached an inflexion point and he reiterates his "strong buy" and 300p target price.

I see that IC have now corrected their earlier report and show the increase as 100%. I look forward to Simon Thompson's update.

Misleading report in IC online market summary this morning. They say EUS up 11% at £92.31m. In fact, up 100% per the 2017 Financial highlights in this mornings RNS: "1h2017 End User Spend (EUS) increased 100% YoY to £92.31m (1h2016: £46.17m). Annualized EUS exiting August 2017 was over £400m, at least 140% more than the rate entering September 2016 (£167m). Revenue from EUS increased 114% YoY to £1.65m (1h2016: £0.77m). Improved Adjusted LBITDA* -£1.01m (1h2016: -£1.64m). Operating costs stable at £2.72m (1h2016: £2.49m) in-line with forecast Cash of £5.6m on 30 June 2017 (30 June 2016: £7.2m; 31 Dec 2016: £5.7m), sufficient to fund the Group through to profitability" Have not had time to read the whole RNS, but assume there must be a typo or more fundamental errors in the IC report. Hope that Simon Thompson will review in more details shortly. Looks pretty good to me!

Simon Thompson in today's on line IC article confirms his buy recommendation with a target of 70p

Rise due to UBS upgrade from neutral to buy and increase in price target from 125 to 145p

Simon Thompson in Investors Chronicle has an article today discussing the half year results. He confirms his buy recommendation for what he describes as a robust second half.